TrialProceedings of the National Academy of Sciences of the United States of America2006

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

Bibiana Bielekova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.